AI together now?

From AI pilots to regulator-ready capabilities

Data science teams in pharma rarely struggle to build promising AI models. The harder challenge is turning those models into capabilities that can withstand regulatory scrutiny long after deployment.

This is where many organisations encounter the glass ceiling of AI. Proofs of concept are plentiful, yet relatively few models make it into critical clinical and operational workflows.

The question is no longer whether AI can deliver value. It is whether organisations can operationalise AI in a way that remains credible, traceable and governable over time.

Many of the barriers are familiar. Models perform well during development but face uncertainty once they leave controlled environments.

Ownership becomes unclear and validation approaches vary between teams. Documentation is fragmented and regulatory expectations can feel difficult to interpret.

Recent regulatory guidance has provided a clearer framework. Both the FDA and global regulators increasingly emphasise risk-based validation, life cycle management, data governance and human oversight.

Increasingly, organisations must demonstrate not only what an AI model does, but that it remains fit for its intended purpose throughout its life cycle.

Two concepts sit at the centre of that discussion: context of use and model risk.
Context of use defines the precise role a model plays in answering a particular question. Model risk considers both how much influence the model has on a decision and the consequences if that decision is wrong.

These distinctions matter because not every AI application carries the same level of risk. A model helping to identify data anomalies in a clinical study requires a different level of scrutiny from one influencing patient safety decisions or supporting regulatory evidence generation.

The more clearly organisations define context and risk at the outset, the easier it becomes to determine appropriate validation, documentation and monitoring requirements.

Once context and risk are understood, the challenge shifts to operationalisation.
Organisations need confidence in the provenance of their data, the reproducibility of their models and the robustness of their evaluation processes. They also need governance structures that persist after deployment.

AI credibility is not established once and then forgotten. It must be maintained.
This is where ModelOps is increasingly more important. Monitoring for data drift, performance degradation and changing operating conditions allows organisations to identify issues before they affect critical decisions.

Equally important is maintaining clear version control, documented change management and accountability throughout the model life cycle.

Without these foundations, trust in AI can quickly outpace the evidence needed to support it.

Regulators continue to emphasise that governance extends beyond the model itself. The focus is progressively on the broader human-AI system.

That means understanding how outputs are used, how decisions are reviewed and how users can challenge or investigate recommendations when necessary. It also means ensuring models are deployed only in populations and environments where performance is properly tested and understood.

For data science and biostats leaders, the opportunity is to turn these principles into repeatable processes. Start every initiative with a clearly defined context of use and risk assessment.

Build credibility, monitoring and governance into the life cycle from the outset. Partner closely with quality and regulatory teams rather than treating governance as a downstream activity.

Ultimately, success is becoming less about model sophistication and more about operational discipline. The organisations making the greatest progress are not necessarily those building the most models. They are the ones creating the foundations that allow AI to be deployed, monitored and governed consistently over time.

That is how teams move beyond the glass ceiling of proofs of concept and towards a future where taking an AI model from idea to regulator-ready deployment becomes a matter of disciplined execution rather than reinvention.